Hence, providing evidence that epigenetic silencing of HTATIP2 may represent an underlying mechanism contributing to resistance to alkylating agent therapy that has been associated with nuclear MPG in GBM patients treated in the clinical trial testing TMZ [18]. The gene discussed is HTATIP2; the disease is glioblastoma.